Trevena Inc. (TRVN) 5.42 $TRVN
Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain
Business Wire - Mon Feb 09, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced positive data from a Phase 1 multiple ascending dose study of TRV734, a novel drug candidate in development as an orally administered treatment for moderate-to-severe acute and chronic pain. TRV734 showed pharmacokinetics, safety, tolerability, and CNS activity consistent with a previous Phase 1 study, and showed effectiveness similar to immediate-release oxycodone in an experimental pain model.
TRVN: 5.42 (+0.15)
Trevena CEO to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present a company overview at the 17th Annual BIO CEO & Investor Conference on Tuesday February 10, 2015 at 8:00 a.m. EST in New York City.
TRVN: 5.42 (+0.15)
TRV027 Phase 2b BLAST-AHF Trial Design Published in Journal of the American College of Cardiology: Heart Failure
Business Wire - Tue Feb 03, 6:01AM CST
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery of G protein coupled receptor (GPCR) biased ligands, today announced publication of the trial design for its ongoing Phase 2b study of TRV027 in acute heart failure (AHF) in the Journal of the American College of Cardiology: Heart Failure. The abstract of the manuscript, entitled "Heart Failure Therapeutics Based on a Biased Ligand of the Angiotensin-2 Type 1 Receptor: Rationale and Design of the BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure) Study," can be viewed online at the JACC:HF website, http://heartfailure.onlinejacc.org/Onlinefirst.aspx. A summary of the study design was previously presented at the 2014 World Congress on Acute Heart Failure.
TRVN: 5.42 (+0.15)
Trevena Initiates Second Phase 2b Study of TRV130 for Acute Postoperative Pain
Business Wire - Tue Jan 06, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced the initiation of a Phase 2b clinical trial of TRV130 for acute postoperative pain in patients following abdominoplasty surgery. TRV130 is a small molecule biased ligand at the mu-opioid receptor that Trevena is developing as a first-line intravenous treatment for patients experiencing moderate-to-severe acute pain.
TRVN: 5.42 (+0.15)
Acute Heart Failure - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4c2c74/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute heart failure and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute heart failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute heart failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. - Nyken BV - Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4c...cute_heart
TRVN: 5.42 (+0.15), AMGN: 153.48 (+0.30), NVS: 102.20 (-0.17)
Nasdaq stocks posting largest percentage decreases
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TRVN: 5.42 (+0.15), SNFCA: 5.78 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:44AM CST
TRVN: 5.42 (+0.15), EXXI: 4.00 (+0.42), NES: 3.52 (+0.13), ASPS: 22.32 (+0.09), CAMP: 18.55 (+0.07), ZAZA: 2.17 (+0.08), EXE: 1.51 (-0.02), VII: 1.47 (-0.02), NQ: 3.95 (-0.03), ARDX: 17.14 (+0.71), SRNE: 11.41 (+0.56), VRTB: 3.31 (-0.28), ANFI: 8.84 (-0.42), ATOS: 1.67 (+0.11), WATT: 9.43 (+0.01), COOL: 1.19 (unch), AMBR: 8.37 (+0.13), WRES: 1.27 (+0.01), SPP: 1.36 (unch), KONE: 4.20 (+0.03)
Trevena Appoints Anne M. Phillips to the Board of Directors
Business Wire - Wed Dec 17, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Anne M. Phillips, M.D. has been appointed to Trevena's Board of Directors. Dr. Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the Board following the Company's initial public offering earlier this year.
TRVN: 5.42 (+0.15)
Trevena (TRVN) in Focus: Stock Rallies 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:44AM CST
Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares surge over 7% on the day.
BIIB: 391.66 (-0.45), TRVN: 5.42 (+0.15), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
InsiderInsights.com Daily Round Up 12/10/14: PSEC, TWI, SGEN, ATLS
InsiderInsights - at Seeking Alpha - Thu Dec 11, 12:18AM CST
TRVN: 5.42 (+0.15), HSGX: 8.61 (-0.07), VR: 42.10 (+0.07), LBTYK: 50.78 (+2.40), ATLS: 30.17 (+0.27), UHS: 104.93 (+0.84), CLH: 49.57 (-0.66), WMS: 25.03 (+0.36), ALEX: 40.08 (+0.12), CDW: 37.03 (+0.63), BABY: 36.96 (-0.03), PRSS: 2.95 (-0.08), SGEN: 31.57 (+0.36), CO: 4.75 (-0.06), HBI: 119.12 (+1.27), TWI: 9.63 (+0.04), HSIC: 143.18 (+0.72), PSEC: 8.67 (+0.07), XLRN: 38.02 (+0.07)
Trevena Announces Closing of Public Offering and Partial Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Dec 10, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. In addition, the Company announced today that it closed the sale of an additional 1,598,000 shares of common stock pursuant to the partial exercise of the option to purchase additional shares by the underwriters of the public offering. With this exercise, the Company has sold 12,848,000 shares in this offering, representing net proceeds of approximately $47.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Trevena.
TRVN: 5.42 (+0.15)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.42 (+0.15), JNJ: 99.62 (+1.18), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OMER: 20.63 (+0.13)
Nasdaq stocks posting largest volume increases
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BIRT: 6.60 (+0.01), TRVN: 5.42 (+0.15), ISIG: 3.19 (unch), FIVE: 33.01 (+0.11), OPB: 28.48 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:10AM CST
ANV: 0.97 (-0.03), TRVN: 5.42 (+0.15), RADA: 2.46 (+0.01), GLP: 38.13 (-0.44), QTM: 1.60 (+0.03), AEO: 14.68 (-0.12), FUEL: 14.30 (+0.65), GOL: 3.85 (+0.01), ULTA: 136.66 (+0.59), FIVE: 33.01 (+0.11), BIG: 47.02 (-1.06), ALSK: 1.75 (-0.03)
Trevena prices offering
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 5:59AM CST
TRVN: 5.42 (+0.15)
Trevena Announces Pricing of Public Offering
Business Wire - Thu Dec 04, 6:00PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. The gross proceeds to Trevena from this offering are expected to be approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trevena. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock from Trevena at the public offering price. The offering is expected to close on December 10, 2014, subject to customary closing conditions.
TRVN: 5.42 (+0.15)
Trevena commences stock offering
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:56AM CST
TRVN: 5.42 (+0.15)
Trevena Announces Commencement of Public Offering
Business Wire - Mon Dec 01, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that it intends to offer and sell $40.0 million of shares of its common stock in an underwritten public offering. Barclays Capital Inc., Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers.
TRVN: 5.42 (+0.15)
Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain
Business Wire - Mon Feb 09, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced positive data from a Phase 1 multiple ascending dose study of TRV734, a novel drug candidate in development as an orally administered treatment for moderate-to-severe acute and chronic pain. TRV734 showed pharmacokinetics, safety, tolerability, and CNS activity consistent with a previous Phase 1 study, and showed effectiveness similar to immediate-release oxycodone in an experimental pain model.
TRVN: 5.42 (+0.15)
Trevena CEO to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present a company overview at the 17th Annual BIO CEO & Investor Conference on Tuesday February 10, 2015 at 8:00 a.m. EST in New York City.
TRVN: 5.42 (+0.15)
TRV027 Phase 2b BLAST-AHF Trial Design Published in Journal of the American College of Cardiology: Heart Failure
Business Wire - Tue Feb 03, 6:01AM CST
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery of G protein coupled receptor (GPCR) biased ligands, today announced publication of the trial design for its ongoing Phase 2b study of TRV027 in acute heart failure (AHF) in the Journal of the American College of Cardiology: Heart Failure. The abstract of the manuscript, entitled "Heart Failure Therapeutics Based on a Biased Ligand of the Angiotensin-2 Type 1 Receptor: Rationale and Design of the BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure) Study," can be viewed online at the JACC:HF website, http://heartfailure.onlinejacc.org/Onlinefirst.aspx. A summary of the study design was previously presented at the 2014 World Congress on Acute Heart Failure.
TRVN: 5.42 (+0.15)
Trevena Initiates Second Phase 2b Study of TRV130 for Acute Postoperative Pain
Business Wire - Tue Jan 06, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced the initiation of a Phase 2b clinical trial of TRV130 for acute postoperative pain in patients following abdominoplasty surgery. TRV130 is a small molecule biased ligand at the mu-opioid receptor that Trevena is developing as a first-line intravenous treatment for patients experiencing moderate-to-severe acute pain.
TRVN: 5.42 (+0.15)
Acute Heart Failure - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4c2c74/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute heart failure and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute heart failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute heart failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. - Nyken BV - Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4c...cute_heart
TRVN: 5.42 (+0.15), AMGN: 153.48 (+0.30), NVS: 102.20 (-0.17)
Nasdaq stocks posting largest percentage decreases
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TRVN: 5.42 (+0.15), SNFCA: 5.78 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:44AM CST
TRVN: 5.42 (+0.15), EXXI: 4.00 (+0.42), NES: 3.52 (+0.13), ASPS: 22.32 (+0.09), CAMP: 18.55 (+0.07), ZAZA: 2.17 (+0.08), EXE: 1.51 (-0.02), VII: 1.47 (-0.02), NQ: 3.95 (-0.03), ARDX: 17.14 (+0.71), SRNE: 11.41 (+0.56), VRTB: 3.31 (-0.28), ANFI: 8.84 (-0.42), ATOS: 1.67 (+0.11), WATT: 9.43 (+0.01), COOL: 1.19 (unch), AMBR: 8.37 (+0.13), WRES: 1.27 (+0.01), SPP: 1.36 (unch), KONE: 4.20 (+0.03)
Trevena Appoints Anne M. Phillips to the Board of Directors
Business Wire - Wed Dec 17, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Anne M. Phillips, M.D. has been appointed to Trevena's Board of Directors. Dr. Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the Board following the Company's initial public offering earlier this year.
TRVN: 5.42 (+0.15)
Trevena (TRVN) in Focus: Stock Rallies 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:44AM CST
Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares surge over 7% on the day.
BIIB: 391.66 (-0.45), TRVN: 5.42 (+0.15), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
InsiderInsights.com Daily Round Up 12/10/14: PSEC, TWI, SGEN, ATLS
InsiderInsights - at Seeking Alpha - Thu Dec 11, 12:18AM CST
TRVN: 5.42 (+0.15), HSGX: 8.61 (-0.07), VR: 42.10 (+0.07), LBTYK: 50.78 (+2.40), ATLS: 30.17 (+0.27), UHS: 104.93 (+0.84), CLH: 49.57 (-0.66), WMS: 25.03 (+0.36), ALEX: 40.08 (+0.12), CDW: 37.03 (+0.63), BABY: 36.96 (-0.03), PRSS: 2.95 (-0.08), SGEN: 31.57 (+0.36), CO: 4.75 (-0.06), HBI: 119.12 (+1.27), TWI: 9.63 (+0.04), HSIC: 143.18 (+0.72), PSEC: 8.67 (+0.07), XLRN: 38.02 (+0.07)
Trevena Announces Closing of Public Offering and Partial Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Dec 10, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. In addition, the Company announced today that it closed the sale of an additional 1,598,000 shares of common stock pursuant to the partial exercise of the option to purchase additional shares by the underwriters of the public offering. With this exercise, the Company has sold 12,848,000 shares in this offering, representing net proceeds of approximately $47.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Trevena.
TRVN: 5.42 (+0.15)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.42 (+0.15), JNJ: 99.62 (+1.18), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OMER: 20.63 (+0.13)
Nasdaq stocks posting largest volume increases
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BIRT: 6.60 (+0.01), TRVN: 5.42 (+0.15), ISIG: 3.19 (unch), FIVE: 33.01 (+0.11), OPB: 28.48 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:10AM CST
ANV: 0.97 (-0.03), TRVN: 5.42 (+0.15), RADA: 2.46 (+0.01), GLP: 38.13 (-0.44), QTM: 1.60 (+0.03), AEO: 14.68 (-0.12), FUEL: 14.30 (+0.65), GOL: 3.85 (+0.01), ULTA: 136.66 (+0.59), FIVE: 33.01 (+0.11), BIG: 47.02 (-1.06), ALSK: 1.75 (-0.03)
Trevena prices offering
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 5:59AM CST
TRVN: 5.42 (+0.15)
Trevena Announces Pricing of Public Offering
Business Wire - Thu Dec 04, 6:00PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. The gross proceeds to Trevena from this offering are expected to be approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trevena. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock from Trevena at the public offering price. The offering is expected to close on December 10, 2014, subject to customary closing conditions.
TRVN: 5.42 (+0.15)
Trevena commences stock offering
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:56AM CST
TRVN: 5.42 (+0.15)
Trevena Announces Commencement of Public Offering
Business Wire - Mon Dec 01, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that it intends to offer and sell $40.0 million of shares of its common stock in an underwritten public offering. Barclays Capital Inc., Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers.
TRVN: 5.42 (+0.15)
